UBS Women's Health Innovation: Multiple Large Therapeutic Opportunities
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
UBS highlights women's health as an underappreciated investment vertical, identifying multiple billion-dollar market opportunities with relatively low competition. Despite comprising roughly half the global population, women receive only about 6% of private healthcare capital, and companies solely dedicated to women's health secure less than 1%.
Women experience approximately 25% more time in poor health than men, primarily due to chronic, non-fatal conditions that remain under-diagnosed. Bridging this gender health gap could generate USD 1 trillion in annual global economic value by 2040, including a USD 100 billion opportunity in the US alone by 2030.
The report identifies three primary opportunity areas: whitespace indications like endometriosis and PCOS, optimization of existing markets such as cardiovascular disease, and wearable technology as a horizontal enabler. Endometriosis and PCOS present combined market potentials exceeding USD 200 billion each, yet currently attract less than 2% of women's health funding. Furthermore, roughly 60% of the gender health gap stems from existing interventions performing worse in women rather than biological inevitability.
Wearable devices, already owned by 53% of Americans, will provide crucial longitudinal data to facilitate early diagnosis and clinical trial stratification. UBS anticipates increased sector consolidation over the next two years.